Treating Sickle Cell Disease with pills: A new possibility?
Sickle cell disease (SCD) is a genetic blood disorder characterized by misshapen red blood cells, leading to various complications such as pain episodes, organ damage, and reduced life expectancy. Over the years, significant strides have been in SCD treatment, ranging…
Amgen Lays Off 350 Employees!
In a strategic move following its acquisition of Horizon Therapeutics for a staggering $27.8 billion, Amgen is undergoing significant organizational changes, resulting in the laying off 350 employees. This development was reported by various media outlets on Tuesday. The job…
Researchers finds a leading genetic cause of Alzheimer’s?
Scientists have created a method to detect key fat-filled particles known as lipoproteins in the central nervous system, opening a new view into the workings of the brain. Researchers found that the particles in our nervous system, molecular cousins of…
New gene discovery for cancer patients unresponsive to chemotherapy
Scientists from Queen Mary University of London have discovered two new genes that cause head and neck cancer patients to be resistant to chemotherapy, and that silencing either gene can make cancer cells previously unresponsive to chemotherapy subsequently respond to…
Self-Healing Metals: A Breakthrough Discovery in Nanoscale Fatigue Damage
Researchers from Sandia National Laboratories and Texas A&M University have unveiled a groundbreaking discovery that challenges conventional materials theory. The study, published in the journal Nature, reveals that metals possess an intrinsic ability to self-heal at the nanoscale level, effectively…
Groundbreaking long-acting monoclonal antibody, a collaborative effort between AstraZeneca (AZ) and Sanofi
On July 17, the U.S. Food and Drug Administration granted approval for nirsevimab, marketed under the name Beyfortus, as a groundbreaking (monoclonal antibody) preventive measure against Respiratory Syncytial Virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants during…
Breakthrough Chikungunya Vaccine of Valneva’s: Phase 3 trial Data
Valneva, a renowned global market leader in vaccine development, has published the research clinical data of its Chikungunya Vaccine candidate Phase 3, VLA1553. The groundbreaking results of VLA1553 can be found in the prestigious medical journal, The Lancet. With Chikungunya…
Enhancing Brain Cancer Treatment: Biodegradable Ultrasound Holds Promise
In the realm of brain cancer treatment, one of the major challenges lies in effectively delivering chemotherapy drugs through the tightly coiled blood vessels of the brain. However, a groundbreaking development in the form of a biodegradable ultrasound device could…
Blood test can now diagnose Glut1 deficiency syndrome
Glut1 deficiency syndrome is a rare and disabling neurological disease still relatively unknown to the medical community. A mutation in the SLC2A1 gene in affected patients causes the glucose transporter GLUT1 to malfunction. Since this transporter is responsible for the…
Engineering molecular interactions with machine learning
In 2019, scientists in the joint School of Engineering and School of Life Sciences Laboratory of Protein Design and Immunoengineering (LPDI) led by Bruno Correia developed MaSIF: a machine learning-driven method for scanning millions of protein surfaces within minutes to…
